174 related articles for article (PubMed ID: 32616027)
1. Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report.
Javinani A; Aghaei Meybodi HR; Kavosi H
J Med Case Rep; 2020 Jul; 14(1):87. PubMed ID: 32616027
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of osteoporosis with PTH].
Takeuchi Y
Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
[TBL] [Abstract][Full Text] [Related]
4. Osteoblast as a target of anti-osteoporotic treatment.
Corrado A; Sanpaolo ER; Di Bello S; Cantatore FP
Postgrad Med; 2017 Nov; 129(8):858-865. PubMed ID: 28770650
[TBL] [Abstract][Full Text] [Related]
5. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
6. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
7. A Bone Histomorphometric Analysis of Hypophosphatasia-related Osteoporosis after Teriparatide Treatment.
Mizuno H; Sawa N; Sekine A; Inoue N; Oba Y; Ikuma D; Yamanouchi M; Hasegawa E; Suwabe T; Suzuki H; Hoshino J; Ubara Y
Intern Med; 2023 Jan; 62(1):75-79. PubMed ID: 35650135
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
11. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide and osseous regeneration in the oral cavity.
Bashutski JD; Eber RM; Kinney JS; Benavides E; Maitra S; Braun TM; Giannobile WV; McCauley LK
N Engl J Med; 2010 Dec; 363(25):2396-405. PubMed ID: 20950166
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
Cosman F; Peterson LR; Towler DA; Mitlak B; Wang Y; Cummings SR
J Clin Endocrinol Metab; 2020 Nov; 105(11):3384-95. PubMed ID: 32658264
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures.
Righetti M; Wach J; Desmarchelier R; Coury F
Joint Bone Spine; 2018 May; 85(3):365-367. PubMed ID: 29246529
[TBL] [Abstract][Full Text] [Related]
17. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
18. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
19. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
20. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
